**Periodic disclosure for the financial products referred to in Article 9, paragraphs 1 to 4a, of Regulation (EU) 2019/2088 and Article 5, first paragraph, of Regulation (EU) 2020/852**

**Product name:**

*Published on: 30 June 2026*

- MPII-COI-JEISYS S.L.P.

**Legal entity identifier:**

- 969500MLLBZXYF1ZDU19

**Sustainable investment** means an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices.

The **EU Taxonomy** is a classification system laid down in Regulation (EU) 2020/852, establishing a list of **environmentally sustainable economic activities**. That Regulation does not include a list of socially sustainable economic activities. Sustainable investments with an environmental objective might be aligned with the Taxonomy or not.

# Sustainable investment objective

**Did this financial product have a sustainable investment objective?**

| ☒ **Yes** | ☐ **No** |
|---|---|
| ☐ It made **sustainable investments with an environmental objective:** ___% | ☐ It **promoted Environmental/Social (E/S) characteristics** and while it did not have as its objective a sustainable investment, it had a proportion of __% of sustainable investments |
| ☐ in economic activities that qualify as environmentally sustainable under the EU Taxonomy | ☐ with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy |
| ☐ in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy | ☐ with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy |
| | ☐ with a social objective |
| ☒ It made **sustainable investments with a social objective:** 100 % | ☐ It promoted E/S characteristics, but **did not make any sustainable investments** |

**To what extent was the sustainable investment objective of this financial product met?**

Sustainable investment is embedded in the asset focus and the management approach of MPII-COI-JEISYS S.L.P. SLP (the "**Fund**") as an impact investment fund focused on contributing to one or more of the 17 United Nations Sustainable Development Goals (‘**UN SDGs’**), mainly SDG #3 “Good health and well-being” and its associated targets, and SDG #9 “Industry, innovation and infrastructure”, and its associated targets, through investments in healthcare companies developing innovative products, medical devices, or services with positive outcomes for patient or animal health conditions. ARCHIMED (the "**Management Company**") has developed a framework (see our Responsible Investment Policy) by which sustainable investments with a social objective can be identified though determining their contribution to ARCHIMED's Health objectives: better efficiency, efficacy, safety, accessibility and affordability. These objectives seek to provide better healthcare outcomes at the doctor, patient, animal, and environmental level, through improvements to medical industries and services to hospitals and care providers.

For our most recent funds (Article 8 (with sustainable investments) and 9), specific healthcare impact objectives and metrics have been relied upon to assess the performance of the sustainable investments. Table 1 provides a summary of 2025 performance.

| | Better efficiency | Better efficacy | Better safety | Better accessibility | Better affordability |
|---|---|---|---|---|---|
| Jeisys Medical | | **Sustainable Investment Objective**: Provide energy-based devices effectively addressing skin diseases with long-lasting effects, reducing the need for multiple sessions. | **Sustainable Investment Objective**: Through its medical-grade devices, ensure patient safety by reducing the prevalence of side effects vs. comparable alternatives in the market. | **Sustainable Investment Objective**: Provide devices designed to effectively treat skin diseases across all Fitzpatrick skin types, ensuring that a broader range of patients can benefit from these treatments. | |
| | | **Sustainable Investment Contribution:** >50% share of revenue contributing to addressing skin diseases. | **Sustainable Investment Contribution:** >40 countries where the medical devices are approved. | **Sustainable Investment Contribution:** 100% Fitzpatrick skin types covered by Radio Frequency and High Intensity Focused Ultrasound devices. | |

*Table 1: MPII-COI-JEISYS S.L.P. 2025 sustainable investments' performance*

Please refer to ARCHIMED's Sustainability & Impact Report for detailed 2025 information on Jeisy's sustainability performance.

**Sustainability indicators** measure how the environmental or social characteristics promoted by the financial product are attained.

### *How did the sustainability indicators perform?*

Jeisys have completed their 2025 ESG reporting. For details on 2025 performance, please refer to Appendix I.

### *…and compared to previous periods?*

As above.

**Principal adverse impacts** are the most significant negative impacts of investment decisions on sustainability factors relating to environmental, social and employee matters, respect for human rights, anti-

***How did the sustainable investments not cause significant harm to any sustainable investment objective?***

MPII-COI-JEISYS S.L.P. 's investment strategy is focused on the contribution to SDG 3 (and where applicable, SDG 9) and associated targets. This strategy dictates that the investments of the Fund will undergo a pre-investment screening and ESG due diligence to ensure that not only does the Fund contribute to social objectives, but that it will do no significant harm' (**DNSH**) to other sustainable investment objectives mainly through the collection and analysis of Principal Adverse Impacts indicators.

Please refer to Appendix I for more information.

*How were the indicators for adverse impacts on sustainability factors taken into account?*

During the investment cycle, the ESG Due diligence assesses indicators that would indicate presence or absence of a principal adverse impact (PAI). These indicators include, in compliance with the SFDR and Delegated regulation, the following principal adverse impacts:

- Environmental damage, GHG emissions; carbon footprint; GHG intensity of Investee companies; exposure to companies active in the fossil fuel sector; share of non-renewable energy consumption and production; energy consumption intensity per high impact climate sector; activities negatively affecting biodiversity-sensitive areas; emissions to water; hazardous waste ratio.

- Social and employee matters, violation of UN Global Compact principles and OECD Guidelines for Multinational Enterprises; lack of processes and compliance mechanisms to monitor compliance with UN Global Compact principles and OECD Guidelines for Multinational Enterprises; unadjusted gender pay gap; board gender diversity; exposure to controversial weapons.

- In addition to the mandatory PAIs, two additional PAIs are taken into account: 1) "Investments in companies without carbon emission reduction initiatives aimed at aligning with the Paris Agreement", which was chosen due to ARCHIMED's focus on climate as a central pillar within our responsible investment strategy; and 2) "Share of investments in investee companies without workplace accident prevention policy" which was selected due to the particular importance of health in safety in the workplace of healthcare businesses, which may be exposed to particular chemicals, machinery or other occupational hazards beyond that of a typical office environment.

Furthermore, our responsible investment strategy is embedded into all steps of our investment lifecycle and is focused on supporting the progress of our investee companies' sustainability performance. For this purpose, we work collaboratively with our investee companies in developing tailored Sustainability and Impact Roadmaps that help set clear objectives, assign internal responsibilities, and monitor progress over time. These Roadmaps are validated at board level and executed by the company's management team as a concrete action plan to advance ESG and sustainability performance, as well as ultimately their PAI results, while also simultaneously contribute to the achievement of the social sustainable objective of the fund. If risks or incidents arise, ARCHIMED identifies any potential corrective action plans and implements active measures to mitigate the identified risks.

To further align business interests with sustainability and impact objectives, ARCHIMED has mandated that a percentage of the CEO's variable remuneration is linked to the achievement of specific objectives of their Sustainability Roadmap, which may improve their PAIs over the holding period.

The ARCHIMED team supports the investee companies in their sustainability journey through regular engagement with company management and monitors company progress against this Roadmap through formal follow-up reviews which are performed on an annual basis. Results on the PAIs for this Fund are available in Appendix I.

*Were sustainable investments aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights? Details:*

Yes, the Management Company ensures investee companies are aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights.

This information is gathered as part of our annual ESG reporting process and is carried out across all portfolios. ARCHIMED policies require MPII-COI-JEISYS S.L.P. to perform appropriate due diligences on its own activities, investments, and business relationships to enable appropriate action to be taken in the event of any findings of non-compliance. ARCHIMED ensures human rights, equality and anti-bribery and corruption policies are in place and that there are not any instances of child, forced, or compulsory labour.

*The EU Taxonomy sets out a "do not significant harm" principle by which Taxonomy-aligned investments should not significantly harm EU Taxonomy objectives and is accompanied by specific Union criteria.*

The "do no significant harm" principle applies only to those investments underlying the financial product that take into account the Union criteria for environmentally sustainable economic activities. The investments underlying the remaining portion of this financial product do not take into account the Union criteria for environmentally sustainable economic activities.

*Any other sustainable investments must also not significantly harm any environmental or social objectives.*

## How did this financial product consider principal adverse impacts on sustainability factors?

PAIs are considered throughout the entire investment cycle, from the initial negative and positive screening phases through due diligence.

During the due diligence phase, an assessment is conducted to verify the company’s readiness to report on PAI metrics. This assessment helps identify existing gaps which can then be addressed in the early stages of onboarding and/or during ARCHIMED annual ESG reporting campaign and hold period.

Our ESG reporting process monitors this by asking investee companies for PAI-related data on an annual basis. Any material impacts are discussed during the annual follow-up reviews, which takes place at the end of the campaign. Please refer to Appendix I for more information.

## What were the top investments of this financial product?

The list includes the investments constituting **the greatest proportion of investments** of the financial product during the reference period which is:

**01/01/25 – 31/12/25**

| Largest investments | Sector | % Assets | Country |
|---|---|---|---|
| Jeisys Medical | Consumer Health | 100 | South Korea |

## What was the proportion of sustainability-related investments?

The proportion of sustainability-related investments in MPII-COI-JEISYS S.L.P. is 100% as the Fund is classified as Article 9 and therefore contributes to sustainable investment objectives.

**Asset allocation** describes the share of investments in specific assets.

*What was the asset allocation?*




As an Article 9 classified fund, MPII-COI-JEISYS S.L.P. 's asset allocation is 100% sustainable investment with social objectives.

To comply with the EU Taxonomy, the criteria for **fossil gas** include limitations on emissions and switching to fully renewable power or low-carbon fuels by the end of 2035. For **nuclear energy**, the criteria include comprehensive safety and waste management rules.

**Enabling activities** directly enable other activities to make a substantial contribution to an environmental objective.

**Transitional activities are** activities for which low-carbon alternatives are not yet available and among others have greenhouse gas emission levels corresponding to the best performance.

*In which economic sectors were the investments made?*

All investments made through MPII-COI-JEISYS S.L.P.  lifetime were made in healthcare industries with 1 investment (100%) in the Consumer Health sector.

**To what extent were the sustainable investments with an environmental objective aligned with the EU Taxonomy?**

MPII-COI-JEISYS S.L.P.  carries out sustainable investments with social objectives as part of our Funds' strategy, which is therefore not based on EU Taxonomy alignment.

Taxonomy-aligned activities are expressed as a share of:
- **turnover** reflecting the share of revenue from green activities of investee companies
- **capital expenditure** (CapEx) showing the green investments made by investee companies, e.g. for a transition to a green economy.
- **operational expenditure** (OpEx) reflecting green operational activities of investee companies.

**Did the financial product invest in fossil gas and/or nuclear energy related activities that comply with EU Taxonomy[1]?**

☐ Yes :

☐ In fossil gas ☐ In nuclear energy

☒ No

***The graphs below show in green the percentage of investments that were aligned with the EU Taxonomy. As there is no appropriate methodology to determine the taxonomy-alignment of sovereign bonds*, the first graph shows the Taxonomy alignment in relation to all the investments of the financial product including sovereign bonds, while the second graph shows the Taxonomy alignment only in relation to the investment of the financial product other than sovereign bonds.***







This graph represents 100% of the total investment.

****For the purpose of these graphs, "sovereign bonds" consist of all sovereign exposure.***

[1] Fossil gas and/or nuclear related activities will only comply with the EU Taxonomy where they contribute to limiting climate change ("climate change mitigation") and do not significantly harm any EU Taxonomy objective – see explanatory note in the left hand margin. The full criteria for fossil gas and nuclear energy economic activities that comply with the EU Taxonomy are laid down in Commission Delegated Regulation (EU) 2022/1214.

**Reference benchmarks** are indexes to measure whether the financial product attains the environmental or social characteristics that they promote.

- ***What was the share of investments made in transitional and enabling activities?***

  Not applicable. The Fund does not invest or plan to invest in transitional nor enabling activities in the sense of the EU Taxonomy.

- ***How did the percentage of investments that were aligned with the EU Taxonomy compared with previous reference periods?***

  Not applicable. MPII-COI-JEISYS S.L.P. 's investments do not follow an environmentally sustainable investment objective in the sense of the EU Taxonomy. Instead, they focus on the attainment of a social sustainable investment objective.

are sustainable investments with an environmental objective that **do not take into account the criteria** for environmentally sustainable economic activities under Regulation (EU) 2020/852.

## What was the share of sustainable investments with an environmental objective not aligned with the EU Taxonomy ?

MPII-COI-JEISYS S.L.P. investments do not pursue an environmental objective as laid out in the EU Taxonomy. Hence, 0% of the Fund's investments are aligned with the EU Taxonomy.

## What was the share of socially sustainable investments ?

100% of MPII-COI-JEISYS S.L.P. investments are sustainable investments with a social objective. For more details, please refer to the above answer to the question; "To what extent was the sustainable investment objective of this financial product met?", as well as our Sustainability and Impact Report.

## What investments were included under "not sustainable", what was their purpose and were there any minimum environmental or social safeguards ?

None of MPII-COI-JEISYS S.L.P. investment fall into this category.

## What actions have been taken to attain the sustainable investment objective during the reference period?

During the reference period, ESG and Impact data were collected for all investee companies, comprising metrics based on SASB and other applicable standards. At the end of the reference period, follow-up reviews were conducted including overall progress, gap analysis and establishment of priorities for 2026.

Specific actions implemented at investee companies' level are specified in our Sustainability and Impact Report, and regularly to our investors in quarterly reports of the Fund.

## How did this financial product perform compared to the reference sustainable benchmark?

Not applicable. The Fund does not use a benchmark.

- ***How does the reference benchmark differ from a broad market index?***

  Not applicable.

- ***How did this financial product perform with regard to the sustainability indicators to determine the alignment of the reference benchmark with the sustainable investment objective?***

  Not applicable.

- ***How did this financial product perform compared with the reference benchmark?***

  Not applicable.

- ***How did this financial product perform compared with the broad market index?***

  Not applicable.

## APPENDIX I: ARCHIMED MPII-COI-JEISYS S.L.P. Principal Adverse Impact Indicators 2025/2024

| Adverse sustainability indicator | | Metric | Unit | 2025 | 2024 | Explanation[12] | Actions Taken[13] |
|---|---|---|---|---|---|---|---|
| **CLIMATE AND OTHER ENVIRONMENT-RELATED INDICATORS** | | | | | | | |
| GHG (Greenhouse Gas) Emissions | 1. GHG emissions (GP share) | Scope 1 GHG emissions and | tonnes | 25 | N/A | In early 2026, Jeisys completed its first full Scope 1, 2, and 3 GHG inventory based on 2025 data, leading to a more accurate disclosure for the reference period. | Jeisys Scope 1 emissions were calculated using an activity-based methodology and scope 2 emissions were measured on a location-based basis. Scope 3 emissions used a mix of activity and monetary data with key areas of improvement identified for future assessments to improve data quality.<br><br>The sustainability roadmap developed in Q1-26 has set out climate-related goals for the short-term including energy consumption reduction through process efficiency improvements, and a mid to long-term ambition to align with 2050 Net Zero Target. |
| | | Scope 2 GHG emissions | tonnes | 71 | N/A | | |
| | | Scope 3 GHG emissions | tonnes | 600 | N/A | | |
| | | Total GHG emissions | tonnes | 696 | N/A | | |
| | 2. Carbon footprint | Carbon footprint | tonnes/ €M | 5 | N/A | | |
| | 3. GHG intensity of investee companies | GHG intensity of investee companies | tonnes/ €M | 34 | N/A | | |
| | 4. Exposure to companies active in the fossil fuel sector | Share of investments in companies active in the fossil fuel sector | % | Nil | N/A | ARCHIMED invests exclusively in companies across the healthcare industries and thus has no exposure to the fossil fuel sector. | Not applicable. |

[12] The Fund has strictly followed the definitions of Annex I of the Final Report on draft Regulatory Technical Standards, dated 4 December 2023, for compiling the various PAI indicators.

[13] For a more detailed overview of ARCHIMED's Responsible Investment strategy at a fund level please refer to MED Platform II SFDR Periodic Disclosure for 2025.

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | 5. Share of non-renewable energy consumption and production | Share of non-renewable energy consumption and non-renewable energy production of investee companies from non-renewable energy sources compared to renewable energy sources, expressed as a percentage | % | 100 | N/A | Jeisys does not currently procure renewable energy, however, actions are currently ongoing to identify measures to reduce non-renewable energy consumption in the coming years. Whilst also continuing to implement measures to improve environmental data collection across all their operational sites. | To address the high reliance on non-renewable energy across its global operations, Jeisys has developed an energy-efficiency program. The plan outlines the ambition to introduce eco-friendly vehicles and transition to renewable electricity sources. Renewable energy procurement has also been built into decarbonization as key action to reduce operational emissions. |
| | 6. Energy consumption intensity per high impact climate sector | Energy consumption in GWh per million EUR of revenue of investee companies, per high impact climate sector | GWh/ €M | 0.01 | N/A | | |
| Biodiversity | 7. Activities negatively affecting biodiversity-sensitive areas | Share of investments in investee companies with sites/operations located in or near to biodiversity-sensitive areas where activities of those investee companies negatively affect those areas | % | Nil | N/A | Jeisys does not have any sites/ operations located in or near biodiversity-sensitive areas where they could negatively affect those areas. | All activities are conducted within established indoor facilities in industrial or commercial zones, with no direct or known negative impact on surrounding ecosystems or biodiversity. |
| Water | 8. Emissions to water | Tonnes of emissions to water generated by investee companies per million EUR invested, expressed as a weighted average | tonnes/ €M | Nil | N/A | Jeisys does not generate emissions to water. | Not applicable. |
| Waste | 9. Hazardous waste ratio | Tonnes of hazardous waste generated by investee companies per million EUR invested, expressed as a weighted average | tonnes/ €M | Nil | N/A | Jeisys is not directly involved in heavy manufacturing in their own operations resulting in no hazardous waste being reported for 2025. It is worth noting that as the company evolves and mature in ESG data collection, the processes of tracking and reporting waste data will improve. This means that reported data may not yet capture the full picture, and values are expected to become more precise and comprehensive in future reporting periods as data maturity improves. | To improve waste monitoring and reporting, Jeisys issued new internal regulations on hazardous waste use and recycling processes are implemented into operational departments to ensure continuous oversight. Jeisys also has introduced material-management practices such as inventory control systems and storage conditions were improved to prevent obsolete-materials waste. |
| ARCHIMED Additional Environmental Indicator | 4. Investments in companies without carbon emission reduction initiatives | Share of investments in investee companies without carbon emission reduction initiatives aimed at aligning with the Paris Agreement | % | 100 | N/A | Formalizing a decarbonization plan and including reduction targets based on the results of the first carbon footprint assessment has been identified as an area of focus for 2026. | Jeisys has begun to identify potential carbon reduction initiatives such as sourcing of renewable energy, the aim is for these actions to be validated by management in 2026 and to begin the implementation of the decarbonization plan. |

| Adverse sustainability indicator | | Metric | Unit | 2025 | 2024 | Explanation[14] | Actions Taken[15] |
|---|---|---|---|---|---|---|---|
| **SOCIAL AND EMPLOYEE, RESPECT FOR HUMAN RIGHTS, ANTI-CORRUPTION AND ANTI-BRIBERY MATTERS** | | | | | | | |
| Social and Employee Matters | 10. Violations of UN Global Compact principles and Organisation for Economic Cooperation and Development (OECD) Guidelines for Multinational Enterprises | Share of investments in investee companies that have been involved in violations of the UNGC principles or OECD Guidelines for Multinational Enterprises | % | Nil | N/A | No violations took place in 2025. | As part of ARCHIMED's Sustainability Essentials framework, investee companies are encouraged to develop and maintain policies on the following non-exhaustive, social and governance topics:<br>(a) Code of Conduct, Anti-Bribery and Corruption, Grievance and Whistleblowing Mechanism<br>(b) Employee Wellbeing & Engagement Approach<br>(c) Responsible Supply Chain<br>(d) Health and Safety<br>(e) Cybersecurity and Data Privacy and Protection<br><br>Potential ESG incidents and controversies are also assessed through multiple channels such as the annual ESG Reporting Campaign and through ongoing engagement with deal team members. ESG topics are also discussed at board level at least twice per year, with ARCHIMED holding multiple board seats across its portfolio.<br><br>In addition to the Sustainability Essentials, ARCHIMED Value Creation Teams (VCTs) support investee companies in strengthening these frameworks, ensuring high standards of corporate governance, accountability, and transparency. |
| | 11. Lack of processes and compliance mechanisms to monitor compliance with UN Global Compact principles and OECD Guidelines for Multinational Enterprises | Share of investments in investee companies without policies to monitor compliance with the UNGC principles or OECD Guidelines for Multinational Enterprises or grievance /complaints handling mechanisms to address violations of the UNGC principles or OECD Guidelines for Multinational Enterprises | % | Nil | N/A | In 2025, Jeisys established a Human Rights Management Policy and Guidelines based on these UNGC and OECD frameworks. This is operationalized through a dedicated channel through which stakeholders can raise concerns or file grievances related to human-rights issues. In parallel, Jeisys has a Code of Ethics in place aligned with global standards. | |

[14] The Fund has strictly followed the definitions of Annex I of the Final Report on draft Regulatory Technical Standards, dated 4 December 2023, for compiling the various PAI indicators.

[15] For a more detailed overview of ARCHIMED's Responsible Investment strategy at a fund level please refer to [MED Platform II SFDR Periodic Disclosure] for 2025.

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Social and Employee Matters | 12. Unadjusted gender pay gap | Average unadjusted gender pay gap of investee companies | % | 17 | N/A | Jeisy's unadjusted pay gap remains in line with industry benchmarks and demonstrates the company's commitment to ensuring fair and equitable pay compensation for all employees.<br><br>Noting, the unadjusted gender pay gap does not account for differences in role, seniority, or function, and as such does not necessarily reflect unequal pay for equivalent work. | Jeisys has a DE&I approach in place to ensure that all employees in the workplace are treated equally. Jeisys are committed to supporting all women in having the opportunity to occupy senior leadership positions and to implement clear initiatives or programs to close any possible salary gaps and career development potential. |
| | 13. Board gender diversity | Average ratio of female to male board members in investee companies | % | 17 | N/A | | |
| | 14. Exposure to controversial weapons (anti-personnel mines, cluster munitions, chemical weapons and biological weapons) | Share of investments in investee companies involved in the manufacture or selling of controversial weapons | % | Nil | N/A | ARCHIMED invests exclusively in companies across the healthcare industries and thus has no exposure to controversial weapons. | Not applicable. |
| ARCHIMED Additional Social Indicator | 1. Investments in companies without workplace accident prevention policies | Share of investments in investee companies without a workplace accident prevention policy | % | Nil | N/A | Jeisys have a global health and safety policy in place across all facilities with prevention measures identified. | During the reference period, Jeisys conducted a workplace and operational-site risk assessment, engaging with industry experts to conduct periodic inspections and trainings across all sites. |